Review our Research

IQuity is committed to transparency and openly sharing our research. Our News & Resources section contains peer-reviewed journal articles, white papers and other information we hope you find helpful.

Learn More

An Autoimmune Disease Diagnostic Breakthrough

For nearly twenty years, studies of changes in DNA have been used to craft associations for disease but cannot always identify the presence or absence of disease. For many autoimmune diseases, the presence of the genetic risk factors does not guarantee that the patient will develop the disease. We have found that RNA gene expression measurements can provide accurate information about real time activity in the immune cells in the blood.

Answers. Not Clues.

IQuity’s research revealed that autoimmune patients exhibit distinct RNA expression patterns in their blood. We believe this is a critical breakthrough in the ability to detect autoimmune disease and related conditions. For example, using the IQIsolate process, our tests can distinguish between diseases in a given specialty - the gastroenterology panel can distinguish between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Within IBD, this technology can also accurately distinguish Crohn’s from ulcerative colitis.

IQuity’s suite of algorithms, IQIsolate, analyzes RNA markers in a blood sample. IQIsolate measures the expression of RNA markers that are extracted from a patient’s blood sample and matches this RNA profile against healthy and sick patient profiles identified through our research. This analysis determines if the patient’s gene expression pattern is consistent with a specific disease.

IQuity’s ability to identify these patterns gives providers information to confirm a suspected diagnosis with analytical accuracy greater than 90%.

RNA Unlocks the Code

Autoimmune patients exhibit discrete RNA expression patterns in their blood that distinguish them from patients whose symptoms mimic autoimmune diseases.

Accurate Results

IQuity’s proprietary process, IQIsolate, uses a suite of algorithms that delivers actionable information for providers to confirm a suspected autoimmune diagnosis with greater than 90% accuracy – in as little as 7 days.

Improved Care

Studies confirm that diagnosing patients early and treating sooner leads to improved care, enhanced patient satisfaction and better long-term outcomes.

Our Research

Research efforts for this novel technology began at Vanderbilt University Medical Center more than 10 years ago, with funding from the National Institutes of Health. The scientists involved realized the impact this discovery would make on millions of patients suffering from autoimmune disease and formed IQuity to commercialize the research. IQuity is validating the IQIsolate test panels which will be available for clinical use in 2017.

The IQIsolate suite of algorithms was built on patient samples from around the globe. Using machine learning methods, researchers were able to distinguish specific autoimmune diseases and related conditions in three medical specialties of neurology, gastroenterology and rheumatology, among these enrolled subjects:

  • Healthy control subjects
  • Patients prior to diagnosis who are then followed in the EMR
  • Patients with disease prior to treatment
  • Patients with established disease
  • Other diseases that are commonly seen by the specialists treating the diseases in our three medical specialties

A Message from Our CEO

Thank you for your interest in IQuity. We recognize patients are looking for answers. We also know that diagnosing and treating patients with autoimmune disease can be challenging. As we developed our research program, we have established a firm commitment to translating bench innovations into clinical practice.

IQuity was founded by scientists leveraging technology developed at Vanderbilt University Medical Center over the last decade. With funding from the National Institutes of Health and private investment, we are now bringing this new technology to communities that are desperately seeking advancements in diagnosis and treatment.

Our commitment is to transparency. IQuity’s science, processes and analytic capabilities are an open book. Through our website, scientific poster presentations and published papers, we are eager to share with you what we do, how we do it and ways we believe we can be of value to the healthcare community.

Chase Spurlock, Ph.D., CEO of IQuity


DNA vs. RNA – Which Holds the Key to Early Disease Diagnosis?

Did you know that genes express themselves in different ways? They do - and they tell a story of an individual’s health and proclivity toward disease.

Learn More »

Peer-Reviewed Articles

Identification of Molecular Biomarkers for Multiple Sclerosis

Quantitative real-time polymerase chain reaction analysis was used to identify a minimum number of genes of which transcript levels discriminated multiple sclerosis patients from patients with other chronic diseases and from controls.

Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis

Results indicate that gene-expression differences in blood accurately exclude or include a diagnosis of MS and suggest that these approaches may provide clinically useful prediction of MS.

Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis

Using machine learning techniques, including support vector machines, this study demonstrates that gene expression signatures can accurately identify subjects with a clinically isolated syndrome who later progress to multiple sclerosis.